Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Sacubitril and valsartan
Medication labelENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart…
Why this: Advisory · dailymed-prescription
ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)]. ENTRESTO is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes.
- generic_name
- sacubitril and valsartan
- product_names
- Sacubitril and Valsartan
- ndc
- 0078-0659, 0078-0659-20, 0078-0659-67, 0078-0659-61, 0078-0659-35, 0078-0777, 0078-0777-20, 0078-0777-67, 0078-0777-61, 0078-0777-35, 0078-9659, 0078-9659-50, 0078-9777, 0078-9777-50, 0078-0696, 0078-0696-20, 0078-0696-67, 0078-0696-61, 0078-0696-35, 0078-1231, 0078-1231-20, 0078-1238, 0078-1238-20
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en